hese are challenging times for governments, public health administrations and the financial markets. While each biopharma company’s primary concern is the health and safety of its team members
In the summer of 2019, Locust Walk launched a blog post, Financing overhang or hangover: The impact on partnerships for public biotech companies, that was born out of observations and conversations with many public, non-revenue generating biotech companies over the years.
Locust Walk has been active in Asia, in particular, Japan for nearly half of the firm’s history and we are deeply rooted in the market. We have advised on more than a dozen transactions during our history in Japan and have successfully helped deal making between US/EU companies and Japan pharma.
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2019 Annual Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life sciences deal landscape.
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Medtech 2019 Annual Report: Global Trends in Medtech Transactions applies the latest data to analyze current activities in the medtech deal landscape.
Based on recent acquisition activity by two of the largest pharmaceutical companies, it seems as if the historical orthodoxy that great biopharma companies are made from the inside out may be losing validity.
CATEGORIES News Events Publications ARCHIVE Chris Ehrlich of Locust Walk to speak at Dartmouth Entrepreneurs Forum On September 6, 2019, Chris
I recently returned from a month in Europe as part of our effort to expand Locust Walk’s European practice. It was an amazing trip meeting great people and learning valuable lessons.
Biotech companies are attracted to licensing deals for a variety of important reasons: 1) to provide an alternative source of capital from the licensee to fund R&D and commercial operations including,
CATEGORIES Advisory boards Asian Capabilities Capital Markets Capital Raising Commercial Assessment Events Finance Locust Walk Institute Market Trends Multitrack Process